Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Promentis Pharmaceuticals
company
About
Promentis Pharmaceuticals focuses on developing antipsychotic drugs to treat schizophrenia.
- 11 - 50
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $1.80M
- Industries
- Biotechnology,Medical,Pharmaceutical
- Founded date
- Jan 1, 2006
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Promentis Pharmaceuticals discovers, develops, and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. Promentis Pharmaceuticals was founded in 2006 and is based in Milwaukee, Wisconsin.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$1.80M
Promentis Pharmaceuticals has raised a total of
$1.80M
in funding over 2 rounds. Their latest funding was raised on
Sep 25, 2012 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 25, 2012 | Grant | $1.80M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Promentis Pharmaceuticals is funded by 1 investors.
National Institutes of Health
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
National Institutes of Health
|
— | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
